Timothy McCarthy, MD
Hematology & Oncology · Fairfax, VANPI 1881963403
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,426 of the $4,955 with a category attached, or 69.1%. 40 manufacturers reported payments, led by EMD Serono, Inc. at 30.3% of the total. Reporting peaked in 2022 at $1,578 and has fallen 52.8% since, to $745 in 2025.
Across 146 payments — averaging $33.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$2K
- AstraZeneca$343
- Amgen$338
- Johnson & Johnson$313
- Novartis$293
- Daiichi Sankyo Inc.$238
- plus $2K from 34 others
Across 216 payments — averaging $3968.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$511K
- Incyte Corporation$154K
- Beigene, Ltd.$80K
- Merck$52K
- EMD Serono, Inc.$23K
- AstraZeneca$21K
- plus $17K from 1 others
What the payments were for
- Consulting fees$1,50030%
- Food & beverage$3,42669%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tepmetko$1,500
- Monoferric$110
How this compares
$4,955 in reported general payments places this provider in the 75th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 52 | $865,535 |
| Lenalidomide | 46 | $617,383 |
| BrukinsaZanubrutinib | 34 | $513,696 |
| RevlimidLenalidomide | 23 | $509,569 |
| PomalystPomalidomide | 14 | $327,010 |
| ZejulaNiraparib Tosylate | 13 | $223,131 |
| XareltoRivaroxaban | 38 | $52,897 |
| EliquisApixaban | 54 | $46,152 |
| Abiraterone Acetate | 13 | $33,474 |
| Hydroxyurea | 59 | $1,182 |
| Imatinib Mesylate | 12 | $884 |
| Dexamethasone | 40 | $773 |
| Anastrozole | 30 | $616 |
| Acyclovir | 24 | $512 |
| Pantoprazole Sodium | 12 | $197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $343 | $865,53552 claims |
| Beigene USA, Inc.Brukinsa | $18 | $513,69634 claims |
| Bristol Myers SquibbRevlimid | $41 | $509,56923 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $65 | $327,01014 claims |
| Johnson & JohnsonXarelto | $313 | $52,89738 claims |
| PfizerEliquis | $100 | $46,15254 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Fairfax
- William ErshlerFairfax$139K
- Sekwon JangFairfax$56K
- Raymond WadlowFairfax$30K
- Daniel ChongFairfax$15K
- Mohamad SalkeniFairfax$12K
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.